Genome Sequencing of Cancer: Identifying Targets and Biomarkers for Therapy
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Biomarkers".
Deadline for manuscript submissions: 25 October 2024 | Viewed by 7932
Special Issue Editor
Interests: liver cancer; hepatocarcinogenesis; genetic analysis; next-generation sequencing; clonal evolution; molecular targeted therapy; therapeutic biomarker; precision medicine
Special Issue Information
Dear Colleagues,
Recent progress in next-generation sequencing has enabled the comprehensive genetic profiling of various cancers, including gastrointestinal, hepatobiliary and pancreatic cancer. After the international projects for cancer genome analyses, the landscape of the driver genes and genetic heterogeneity have been identified in each type of cancer. Importantly, the genetic profile of every tumor differs from one another, and the accumulating knowledge has revealed that the anti-tumor effect by molecular targeted therapies can be influenced by the interpatient heterogeneity of genetic aberrations. Although genetic analyses on clinical cohorts have been conducted worldwide, the pivotal molecular targets and biomarkers predicting the treatment efficacy have not sufficiently been established to date in many sorts of cancer.
The aim of this Special Issue is to present the recent progress on the clinical application of genetic analysis, including the identification of novel therapeutic targets, the early cancer detection, and the exploration of predictive biomarkers based on any genetic testing, which should lead to the realization of the precision medicine. We are inviting relevant original research, systematic reviews, meta-analyses, and short communications covering the above-mentioned topics.
Dr. Haruhiko Takeda
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer genome analysis
- next-generation sequencing
- heterogeneity
- molecular targeted therapy
- therapeutic biomarker
- precision medicine